Publications

1. Aboelatta MA, Zarka J, Tchatchua N, Aboelatta NA, Johnson JE, Jakub JW, Desroches J, Wilson-Miller J, Tabiim A, Behl D, Montane HN, Kottschade LA, Dimou A, Block MS, Heath EI, Doonan B, Seetharam M, Molina JR, Charnin JE, Gill P, Lin Y, Baral B, Markovic SN, Dudek AZ. Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2. Curr Oncol. 2026 Jun 24; 33 (7) Epub 2026 June 24
   View PubMed
2. Brown R, Smith KE, Shanshal MM, Dimou A, Leventakos K, Parikh K, Mansfield AS, Molina JR, Goetz MP, Jatoi A, Cathcart-Rake E. Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support. Support Care Cancer. 2025 Nov 26; 33 (12):1134
   View PubMed
3. Hieken TJ, Zahrieh D, Flotte TJ, Dronca RS, Domingo-Musibay E, Nelson GD, Strand CA, Kottschade LA, Montane HN, Piltin MA, Chen R, McWilliams RR, Jakub JW, Khariwala SS, Dudek AZ, Johnson JE, Markovic SN, Dimou A, Tasche KK, Block MS. NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma. Eur J Cancer. 2025 Sep 9; 227:115688 Epub 2025 Aug 06
   View PubMed
4. Singh A, Sridhar A, Poddar A, Dimou A, Parikh K, Shanshal M, Schwecke A, Moffett N, Patel MR, Mansfield AS, Leventakos K. Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report. JTO Clin Res Rep. 2025 Jun; 6 (6):100807 Epub 2025 Feb 13
   View PubMed
5. Block MS, Nelson GD, Chen J, Johnson S, Yang L, Flotte TJ, Grewal EP, McWilliams RR, Kottschade LA, Domingo-Musibay E, Markovic SN, Dimou A, Montane HN, Piltin MA, Price DL, Khariwala SS, Hui JYC, Erskine CL, Strand CA, Zahrieh D, Dong H, Hieken TJ. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial. J Immunother Cancer. 2025 Apr 15; 13 (4)
   View PubMed
6. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2025 Mar; 639 (8054):E19
   View PubMed
7. Skoulidis F, Li BT, Hochmair M, Govindan R, Vincent M, van der Wekken AJ, Reguart Aransay N, O'Byrne KJ, Girard N, Griesinger F, Nishio M, Hafliger S, Lindsay C, Reinmuth N, Paulus A, Papakotoulas P, Kim SW, Ferreira CG, Pasello G, Duruisseaux M, Gennatas S, Dimou A, Mehta B, Kormany W, Nduka C, Sylvester BE, Ardito-Abraham C, Wang Y, de Langen AJ. Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer. Oncologist. 2025 Jan 17; 30 (1)
   View PubMed
8. Yao Y, Yan Y, Suman VJ, Dietz AB, Erskine CL, Dimou A, Markovic SN, McWilliams RR, Montane HN, Block MS. Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma. Front Immunol. 2025; 16:1491448 Epub 2025 Feb 04
   View PubMed
9. Sridhar A, Singh A, Hansen S, Pulsipher S, Parikh K, Mansfield AS, Dimou A, Molina JR, Smith KE, Garces YI, Park SS, Chaudhuri AA, Merrell KW, Olivier KR, Leventakos K, Owen D, Shanshal M. Safety and efficacy of sequential chemoimmunotherapy followed by concurrent chemoradiation in unresectable stage III NSCLC. JTO Clinical and Research Reports. 2025; 6 (11):100890
   
10. Stoff R, Markovic SN, McWilliams RR, Kottschade LA, Montane HN, Dimou A, Dudek AZ, Tan W, Dronca RS, Seetharam M, Chen R, Block MS. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting. Melanoma Res. 2024 Dec 1; 34 (6):510-518 Epub 2024 Aug 30
    View PubMed
11. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635 (8038):462-471 Epub 2024 Oct 09
    View PubMed
12. Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. J Thorac Oncol. 2024 Nov; 19 (11):1539-1549 Epub 2024 July 15
    View PubMed
13. Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR. Impact of eml4-alk variants and co-occurring tp53 mutations on duration of first-line alk tyrosine kinase inhibitor treatment and overall survival in alk fusion-positive nsclc: real-world outcomes from the guardantinform database. Journal of Thoracic Oncology. 2024 Nov; 19 (11):1539-49
    
14. Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, Lin HM, Dimou A. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Adv Ther. 2024 Aug; 41 (8):3217-3231 Epub 2024 June 25
    View PubMed
15. Jazieh K, Kottschade L, Dimou A. Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy. J Immunother Precis Oncol. 2024 May; 7 (2):126-129 Epub 2024 May 02
    View PubMed
16. Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial. Nat Commun. 2024 Feb 16; 15 (1):1430
    View PubMed
17. Zhao Y, Dimou A, Fogarty ZC, Jiang J, Liu H, Wong WB, Wang C. Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels. Cancer Res Commun. 2024 Feb 5; 4 (2):303-311
    View PubMed
18. Sener U, Webb M, Breen WG, Neth BJ, Laack NN, Routman D, Brown PD, Mahajan A, Frechette K, Dudek AZ, Markovic SN, Block MS, McWilliams RR, Dimou A, Kottschade LA, Montane HN, Kizilbash SH, Campian JL. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. J Immunother Precis Oncol. 2024 Feb; 7(1):1-6. Epub 2024 Feb 05.
    View PubMed
19. Dimou A. Time to Think about HLA-Based Diagnostics in Lung Cancer? Clin Cancer Res 2023 Dec 1; 29 (23):4706-4708
    View PubMed
20. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
21. Peters TL, Chen N, Tyler LC, Le AT, Dimou A, Doebele RC. Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression. Thorac Cancer. 2023 Nov; 14 (33):3259-3265 Epub 2023 Sept 19
    View PubMed
22. Johnson BJ, Guo R, Moore EJ, Price DL, Van Abel KM, Van Gompel JJ, Link MJ, Peris-Celda M, Stokken JK, Pinheiro-Neto C, Kottschade L, Markovic S, Block M, McWilliams R, Montane H, Dimou A, Gergelis K, Gamez ME, Choby G. Sinonasal mucosal melanoma: An analysis of treatment-related adverse events and associated factors. Int Forum Allergy Rhinol. 2023 Jun; 13(6):1037-1041. Epub 2022 Dec 15.
    View PubMed
23. Samhouri BF, Dimou A, Boland JM, Edell ES. Spontaneous Regression of Metastatic Lung Adenocarcinoma Following a Core Biopsy. J Bronchology Interv Pulmonol. 2023 Apr 1; 30 (2):181-184 Epub 2023 Apr 01
    View PubMed
24. Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Perol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. Future Oncol. 2023 Jan; 19 (2):123-135 Epub 2023 Mar 06
    View PubMed
25. Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Front Immunol. 2023; 14:1279387 Epub 2023 Oct 31
    View PubMed
26. Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Schwecke A, Moffett N, Hocum C, Leventakos K, Adjei A, Marks R, Molina J, Mansfield AS, Chen ZM, Dimou A. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023; 36:100743. Epub 2023 Jul 13.
    View PubMed
27. Dimou A. Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients. Vaccines (Basel). 2022 Dec 11; 10 (12)
    View PubMed
28. Dimou A, Lo YC, Merrell KW, Halling KC, Mansfield AS. Small Cell Transformation in a Patient With RET Fusion-Positive Lung Adenocarcinoma on Pralsetinib. JCO Precis Oncol. 2022 Dec; 6:e2200478
    View PubMed
29. Zhao Y, Dimou A, Shen F, Zong N, Davila JI, Liu H, Wang C. PO2RDF: representation of real-world data for precision oncology using resource description framework. BMC Med Genomics. 2022 Jul 30; 15 (1):167 Epub 2022 July 30
    View PubMed
30. Davidson TM, Markovic SN, Dimou A. The immunologic balance: three cases of rituximab-associated melanoma. Melanoma Res. 2022 Feb 1; 32 (1):67-70
    View PubMed
31. Dimou A, Nasarre C, Peterson YK, Pagano R, Gooz M, Nasarre P, Drabkin HA, Armeson KE, Gibney BC, Gemmill RM, Denlinger CE. Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer Journal of Thoracic and Cardiovascular Surgery. 2021 Aug; 162 (2):463-73
    
32. Winfree KB, Molife C, Peterson PM, Chen Y, Visseren-Grul CM, Leusch MS, Beyrer J, Dimou A. Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations. Future Oncol. 2021 Aug; 17 (22):2867-2881 Epub 2021 Apr 19
    View PubMed
33. Pranitha Prodduturvar, Konstantinos Leventakos, Ashley Potter, Robert W. Gao, Anastasios Dimou, Randolph Marks, Yolanda I. Garces, Kenneth R. Olivier, Julian R. Molina, Kenneth Merrell, Aaron Scott Mansfield, Alex A. Adjei, Anna Schwecke, Craig Hocum, Jenesse Nicole Moffett, Sean Sunghun Park, Dawn Owen. Single institution toxicity of definitive chemoradiation and maintenance durvalumab in locally advanced non-small cell lung cancer. Journal of Clinical Oncology. 2021; 39(15).
    
34. Dimou A, Grewe P, Sidney J, Sette A, Norman PJ, Doebele RC. HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. J Thorac Oncol. 2021 Jan; 16 (1):104-112 Epub 2020 Sept 11
    View PubMed
35. Uprety D, Parikh K, Sawkar A, Dimou A, Leventakos K. Changing paradigm in advanced and metastatic non-small cell lung cancer. J Thorac Dis. 2020 Nov; 12 (11):6992-7001
    View PubMed
36. Matthew, Vera, Wendy, Heidi, Jill, Carrie, Anastasios, Lisa, Yiyi, Joel, Craig, Svetomir, Robert. A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for unresectable stage IV malignant melanoma (MM): MC1371 (NCT02020707). Journal of Clinical Oncology. 2020; 38(15).
    
37. Dimou A, Barron G, Merrick DT, Kolfenbach J, Doebele RC. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. BMC Cancer. 2020 Mar 4; 20 (1):177 Epub 2020 Mar 04
    View PubMed
38. Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Front Oncol. 2020; 10:510 Epub 2020 Apr 15
    View PubMed
39. Dimou A, Syrigos KN. The Role of GSK3beta in T Lymphocytes in the Tumor Microenvironment. Front Oncol. 2020; 10:1221 Epub 2020 July 24
    View PubMed
40. Dimou A, Camidge DR. Detection of NRG1 Fusions in Solid Tumors: Rare Gold? Clin Cancer Res 2019 Aug 15; 25 (16):4865-4867 Epub 2019 June 11
    View PubMed
41. Adam C Soloff, Rebecca A. Stanton, Nicholas M. Radio, Maria Freilino-Glunt, Cecile Nasarre, Anastasios Dimou, Patrick Nasarre, Chadrick E. Denlinger, Steffi Oesterreich, Adrian V. Lee, Michael T. Lotze, Rajeev Dhupar and Robert Gemmill. Neuropilin-2 Isoforms Regulate Distinct Functions of Tumor-associated Macrophages in Breast Cancer The Journal of Immunology. 2019; 202(1).
    
42. Dimou A, Bamias A, Gogas H, Syrigos K. Inhibition of the Hedgehog pathway in lung cancer. Lung Cancer. 2019 Jul; 133:56-61 Epub 2019 May 06
    View PubMed
43. Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, Aisner DL, Gao D, Ren S, Camidge DR. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. J Thorac Oncol. 2019 Apr; 14 (4):596-605 Epub 2018 Dec 10
    View PubMed
44. Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer. 2019 Apr 1; 125 (7):1038-1049 Epub 2018 Dec 11
    View PubMed
45. Bunn PA Jr, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13; 33 (3):101-6, 109
    View PubMed
46. Dimou A, Ou SI, Doebele RC. Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation. JCO Precis Oncol. 2019; 3 Epub 2019 June 03
    View PubMed
47. Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 Nov 1; 24 (21):5250-5260 Epub 2018 July 18
    View PubMed
48. Bunn PA Jr, Dimou A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. J Clin Oncol 2018 Sep 1; 36 (25):2571-2574 Epub 2018 July 20
    View PubMed
49. Pacheco JM, Dimou A, Bunn PA. Advances in lung cancer. Oncotarget 2017 Oct 3; 8 (45):78247-78248 Epub 2017 Sept 13
    View PubMed
50. Dimou A, Dincman T, Evanno E, Gemmill RM, Roche J, Drabkin HA. Epigenetics during EMT in Lung Cancer: EZH2 as a potential therapeutic target. Cancer Treatment and Research Communications. 2017; 12:40-8.
    
51. Dimou A, Sherman C, Wrangle J. Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. J Thorac Imaging. 2016 Jul; 31 (4):238-42
    View PubMed
52. Makatsoris T, Tsamandas AC, Strimpakos A, Alexopoulou Z, Dionysopoulos D, Pervana S, Konstantara A, Papakostas P, Samantas E, Rallis G, Dimou A, Pentheroudakis G, Papaparaskeva K, Psyrri A, Kalogeras KT, Syrigos K, Scopa CD, Fountzilas G. HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. Anticancer Res. 2016 Apr; 36 (4):1581-90
    View PubMed
53. Perelas A, Dimou A, Saenz A, Rhee JH, Teerapuncharoen K, Rowden A, Eiger G. CT pulmonary angiography utilization in the emergency department: diagnostic yield and adherence to current guidelines. Am J Med Qual. 2015 Nov-Dec; 30 (6):571-7 Epub 2014 July 18
    View PubMed
54. Perelas A, Dimou A, Saenz A, Rhee JH, Teerapuncharoen K, Rowden A, Eiger G. Incidental findings on computed tomography angiography in patients evaluated for pulmonary embolism. Ann Am Thorac Soc. 2015 May; 12 (5):689-95
    View PubMed
55. Davila CD, Vargas F, Huang KH, Monaco T, Dimou A, Rangaswami J, Figueredo VM. Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events. Platelets. 2015; 26 (7):651-6 Epub 2014 Oct 29
    View PubMed
56. Chae YK, Dimou A, Pierce S, Kantarjian H, Andreeff M. The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma. 2014 Dec; 55 (12):2822-9 Epub 2014 Apr 29
    View PubMed
57. Dimou A, Papadimitrakopoulou V. Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J Pers Med. 2014 Jun 30; 4 (3):386-401 Epub 2014 June 30
    View PubMed
58. Chae YK, Khemasuwan D, Dimou A, Neagu S, Chebrolu L, Gupta S, Carpio A, Kim J, Yun JH, Smyrlis A, Friedman A, Tester W. Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease. PLoS One. 2014; 9 (1):e87813 Epub 2014 Jan 31
    View PubMed
59. Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS One. 2014; 9 (9):e107677 Epub 2014 Sept 18
    View PubMed
60. Nguyen HC, Dimou A, Govil A, Balasubramanian M, Jacobs-Kosmin D. Primary antiphospholipid syndrome and necrotizing pancreatitis: a diagnostic challenge. J Clin Rheumatol. 2013 Sep; 19 (6):348-50
    View PubMed
61. Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Ann Oncol. 2013 Aug; 24 (8):2124-31 Epub 2013 Feb 13
    View PubMed
62. Dimou A, Syrigos KN, Saif MW. Update on novel therapies for pancreatic neuroendocrine tumors: 2013. JOP. 2013 Jul 10; 14 (4):377-80 Epub 2013 July 10
    View PubMed
63. Anastasios Dimou, Konstantinos N Syrigos, Muhammad Wasif Saif. Novel Agents in the Treatment of Pancreatic Adenocarcinoma Journal of the Pancreas. 2013; 14(2):138-140.
    
64. Dimou A, Neumeister V, Agarwal S, Anagnostou V, Syrigos K, Rimm DL. Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer. Am J Pathol. 2012 Oct; 181 (4):1436-42 Epub 2012 Aug 08
    View PubMed
65. Dimou A, Syrigos KN, Saif MW. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol. 2012 Sep; 4 (5):271-9
    View PubMed
66. Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL. Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. Cancer. 2012 Mar 15; 118 (6):1607-18 Epub 2011 Aug 25
    View PubMed
67. Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Gould Rothberg B, Zolota V, Syrigos K, Rimm DL. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol. 2011 Aug; 179 (2):580-9 Epub 2011 June 12
    View PubMed
68. Dimou A, Syrigos K, Saif MW. Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer. Anticancer Drugs. 2011 Jun; 22 (5):384-91
    View PubMed
69. Dimou AT, Syrigos KN, Saif MW. Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP. 2011 Mar 9; 12 (2):114-6 Epub 2011 Mar 09
    View PubMed
70. Dimou A, Harrington K, Syrigos KN. From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Patholog Res Int. 2011; 2011:312346 Epub 2011 July 18
    View PubMed
71. Dimou AT, Syrigos KN, Saif MW. Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP. 2010 Jul 5; 11 (4):324-7 Epub 2010 July 05
    View PubMed
72. Dimou A, Syrigos KN, Saif MW. Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opin Investig Drugs. 2010 Jun; 19 (6):723-35
    View PubMed
73. Dimou AT, Syrigos KN, Saif MW. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP. 2010 Mar 5; 11 (2):135-8 Epub 2010 Mar 05
    View PubMed
74. Dimou A, Syrigos KN, Saif MW. Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol. 2009 Aug 14; 15 (30):3734-43
    View PubMed